Invasive meningococcal disease (IMD) is responsible for serious morbidity and mortality with global estimates of 50,000-135,000 deaths annually. Due to the early non-specific symptoms of IMD, misdiagnosis is common and often results in late medical intervention. Despite the availability of antibiotic therapy, case fatality rate for IMD serogroups B and C among Australian children below 5 years of age is 5%; and 6-12% for adults over the age of 25. Moreover approximately 10-30% of people who survive IMD develop long-term consequences such as limb deformity, limb scarring, deafness and neurological deficits. In this program GPs can update their IMD awareness so that they are more familiar with which variants of IMD are prevalent, how to diagnose it, how to recommend vaccinations and make sure all at risk groups are covered with immunisations.
This activity has been approved by The Royal Australian College of General Practitioners QI&CPD Program. Total Points: 4 Point(s) (Category 2)
Robina Town Centre Medical Centre, QLD
Professor Robert Booy
MBBS (Hons), MSc, MD, FRACP, FRCPCH
Head, Clinical Research
National Centre for Immunisation Research and Surveillance
Westmead Children’s Hospital
On completion of this program, GPs will be better able to:
- Identify at-risk patient groups who require meningococcal B vaccination and review current Australian incidence of Meningococcal B across the age groups.
- Recall common reasons for vaccine hesitancy in at-risk meningococcal B patients.
- Incorporate patient communication strategies to enhance patient confidence in meningococcal B vaccine.
- Implement practical tips and communication techniques to optimise communication with parents and assist them to make safe and informed immunisation choices for their children.